TOWER ONE WIRELESS ANNOUNCES TWENTY- SIX TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $2,600,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF AUGUST 2022VANCOUVER, BC, CANADA , Sept. 14, 2022 (GLOBE NEWSWIRE) -- TOWER...
COVID-19
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -...
TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to...
OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health
BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management...
Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions...
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
Data include the persistence of immune responses and protection against variants of concern, especially Delta and OmicronOcugen has North American...
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small Intestine for Treatment of Any Disease Including Type 2...
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Study has reached extended enrollment target of 160 patients Top-line data...
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
TriLink BioTechnologies, Part of Maravai LifeSciences, Expands its mRNA Raw Material Offering with the First GMP-grade Modified Nucleoside-Triphosphate Product
TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and...
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal...
Dyadic Updates Market on Recent Scientific Achievements
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...